Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + clarithromycin + metronidazole triple therapy for H. pylori in penicillin-allergic patients
jRCTs031200171Active, not recruiting
- Sponsor
- Yokohama City University
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan, clarithromycin and metronidazole in Helicobacter pylori infection, sponsored by Yokohama City University. Primary endpoint: Eradication rate. Started Dec 2020; status: active, not recruiting.
02
Drugs
vonoprazanclarithromycinmetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031200171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200171.